/TIL
TIL Stock - Instil Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$11.27+1.58%
+$0.17 (+1.58%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.36
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+435.3%upside
Target: $60.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TIL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.16 – $11.38
TARGET (TP)$60.33
STOP LOSS$10.37
RISK/REWARD1:54.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.10
52W High$42.79
52W Low$10.69
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $138,000 |
| Gross Profit | N/A | N/A | $-5,987,000 | N/A | $138,000 |
| Gross Margin | N/A | N/A | N/A | N/A | 100.0% |
| Operating Income | $-73,541,000 | $-159,169,000 | $-206,170,000 | $-155,560,000 | $-33,644,000 |
| Net Income | $-74,135,000 | $-156,087,000 | $-223,177,000 | $-156,794,000 | $-37,738,000 |
| Net Margin | N/A | N/A | N/A | N/A | -27346.4% |
| EPS | $-11.39 | $-24.00 | $-34.46 | $-29.60 | $-5.89 |
Company Overview
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
33%
Hold / Neutral
2
67%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish2 Neutral/Bearish
Price Targets
$23
Average Target
↑ 104.1% Upside
Now
$6
Low
$23
Average
$52
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 7th 2025 | Jefferies | Upgrade | Buy | $52← $11 |
| November 4th 2024 | JMP Securities | Initiation | Market Perform | - |
| April 12th 2024 | Jefferies | Downgrade | Hold | $11← $5 |
| November 1st 2022 | Truist | Downgrade | Hold | $6← $16 |
| November 1st 2022 | Cowen | Downgrade | Market Perform | - |
Earnings History & Surprises
TILBeat Rate
39%
Last 18 quarters
Avg Surprise
-132.9%
EPS vs Estimate
Beats / Misses
7/9
2 met exactly
Latest EPS
$-2.01
Q4 2025
EPS Surprise History
Q1 24
+29.9%
$-1.99vs$-2.84
Q2 24
-73.1%
$-3.74vs$-2.16
Q3 24
+24.7%
$-2.29vs$-3.04
Q4 24
-70.2%
$-3.54vs$-2.08
Q1 25
+51.5%
$-1.82vs$-3.75
Q2 25
-113.9%
$-4.32vs$-2.02
Q3 25
-88.4%
$-3.24vs$-1.72
Q4 25
-0.5%
$-2.01vs$-2.00
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $-2.31 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-2.00 | $-2.01 | -0.5% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-1.72 | $-3.24 | -88.4% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-2.02 | $-4.32 | -113.9% | ✗ MISS |
Q1 2025 | Mar 4, 2025 | $-3.75 | $-1.82 | +51.5% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-2.08 | $-3.54 | -70.2% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-3.04 | $-2.29 | +24.7% | ✓ BEAT |
Q2 2024 | May 10, 2024 | $-2.16 | $-3.74 | -73.1% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-2.84 | $-1.99 | +29.9% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-2.80 | $-10.40 | -271.4% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-4.00 | $-2.20 | +45.0% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-9.00 | $-7.20 | +20.0% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-0.41 | $-8.29 | -1922.4% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-8.80 | $-7.40 | +15.9% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-8.00 | $-8.00 | 0.0% | = MET |
Q2 2022 | May 16, 2022 | $-7.60 | $-7.20 | +5.3% | ✓ BEAT |
Q1 2022 | Mar 7, 2022 | $-7.40 | $-8.60 | -16.2% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-6.60 | $-6.60 | 0.0% | = MET |
Q3 2021 | Aug 12, 2021 | $-4.20 | $-5.40 | -28.6% | ✗ MISS |
Latest News
Instil Bio Q3 Adj. EPS $(1.75) Beats $(2.35) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 12:11 PM
HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target
📈 PositiveBenzinga•Sep 11, 2025, 01:30 PM
Instil Bio Says ImmuneOnco Biopharma Presents Preliminary Efficacy And Safety Data Of '2510 As Monotherapy In Phase 1 Study Of Patients In China With Previously Treated Sq-NSCLC At 2025 WCLC
➖ NeutralBenzinga•Sep 10, 2025, 11:13 AM
HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target
📈 PositiveBenzinga•Aug 27, 2025, 11:10 AM
Instil Bio Posts Wider Loss in Q2
📉 NegativeThe Motley Fool•Aug 13, 2025, 11:09 AM
Instil Bio shares rise on immunotherapy trial updates
📈 PositiveSeeking Alpha•May 22, 2025, 03:31 PM
Frequently Asked Questions about TIL
What is TIL's current stock price?
Instil Bio, Inc. (TIL) is currently trading at $11.27 per share. The stock has moved +1.58% today.
What is the analyst price target for TIL?
The average analyst price target for TIL is $60.33, based on 1 analyst.
What sector is Instil Bio, Inc. in?
Instil Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TIL's market cap?
Instil Bio, Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does TIL pay dividends?
No, Instil Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATOS
Atossa Therapeutics, Inc.
$0.73
Mkt Cap: $0.1B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
ONCY
Oncolytics Biotech Inc.
$1.01
Mkt Cap: $0.1B
PLRX
Pliant Therapeutics, Inc.
$1.23
Mkt Cap: $0.1B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
STTK
Shattuck Labs, Inc.
$3.15
Mkt Cap: $0.2B
TVGN
Tevogen Bio Holdings Inc.
$0.38
Mkt Cap: $0.1B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
ZNTL
Zentalis Pharmaceuticals, Inc.
$1.40
Mkt Cap: $0.1B
Explore stocks similar to TIL for comparison